Gonzales AJ, Hook KE, Althaus IW, Ellis PA

[1] Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, et all. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008 Jul;7(7):1880-9. doi: 10.1158/1535-7163.MCT-07-2232. Epub 2008 Jul 7.
[2] Mok T, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, et all. Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. J Clin Oncol 35, 2017 (suppl; abstr LBA9007).
[3] ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. (ARCHER 1050) – Clinicaltrial.gov Website NCT01774721. Last accessed June 5, 2017